Cancer recurrence monitoring using hyperpolarized [1-13C]pyruvate metabolic imaging in murine breast cancer model
10.1016/j.mri.2017.07.014 · doi-reference
13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression
10.1016/j.cmet.2011.04.012 · doi-reference
MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition
10.1016/j.ccell.2016.12.005 · doi-reference
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours
10.1111/bcp.14289 · doi-reference
Identifying strategies to target the metabolic flexibility of tumours
10.1038/s42255-020-0195-8 · doi-reference
Targeting lipid metabolism in metastatic prostate cancer
10.1177/17588359231152839 · doi-reference
Fatty acid synthase: an emerging target in cancer
10.3390/molecules25173935 · doi-reference
Pivotal role of fatty acid synthase in c-MYC driven hepatocarcinogenesis
10.3390/ijms21228467 · doi-reference
Myc-Driven glycolysis is a therapeutic target in glioblastoma
10.1158/1078-0432.ccr-15-2274 · doi-reference
MYC in cancer: from undruggable target to clinical trials
10.1038/s41573-025-01143-2 · doi-reference
The insulin and IGF signaling pathway sustains breast cancer stem cells by IRS2/PI3K-mediated regulation of MYC
10.1016/j.celrep.2022.111759 · doi-reference
Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes
10.1186/bcr3089 · doi-reference
Rethinking the relationship between insulin and cancer
10.1016/j.tem.2020.05.004 · doi-reference
Obesity and cancer, a case for insulin signaling
10.1038/cddis.2015.381 · doi-reference
Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-Myc
10.1038/s42255-024-01037-4 · doi-reference
The fat side of prostate cancer
10.1016/j.bbalip.2013.03.010 · doi-reference
The metabolic fate of acetate in cancer
10.1038/nrc.2016.87 · doi-reference
Acetate metabolism in physiology, cancer, and beyond
10.1016/j.tcb.2019.05.005 · doi-reference
Proinflammatory CXCL12-CXCR4/CXCR7 signaling axis drives Myc-induced prostate cancer in Obese mice
10.1158/0008-5472.can-17-0284 · doi-reference
Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
10.1136/bmj.g7607 · doi-reference
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies
10.1016/s0140-6736(08)60269-x · doi-reference
Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5-24 million UK adults
10.1016/s0140-6736(14)60892-8 · doi-reference
Targeting MYC at the intersection between cancer metabolism and oncoimmunology
10.3389/fimmu.2024.1324045 · doi-reference
Immunoediting instructs tumor metabolic reprogramming to support immune evasion
10.1016/j.cmet.2022.12.003 · doi-reference
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid
10.1038/nature13490 · doi-reference
Lactate in the tumour microenvironment: from immune modulation to therapy
10.1016/j.ebiom.2021.103627 · doi-reference
MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of proinflammatory macrophages
10.1158/0008-5472.can-22-0232 · doi-reference
Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells
10.1038/s41556-018-0083-6 · doi-reference
MIF loss impairs Myc-induced lymphomagenesis
10.1038/sj.cdd.4401653 · doi-reference
Breast cancer stem cells secrete MIF to mediate tumor metabolic reprogramming that drives immune evasion
10.1158/0008-5472.can-23-2390 · doi-reference
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma
10.1016/j.ccr.2008.10.016 · doi-reference
HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice
10.1038/s41467-020-17873-3 · doi-reference
Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1
10.1128/mcb.00440-07 · doi-reference
Intestinal MYC modulates obesity-related metabolic dysfunction
10.1038/s42255-021-00421-8 · doi-reference
HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity
10.1016/j.ccr.2007.04.001 · doi-reference
Molecular crosstalk between MYC and HIF in cancer
10.3389/fcell.2020.590576 · doi-reference
Tumour hypoxia in driving genomic instability and tumour evolution
10.1038/s41568-024-00781-9 · doi-reference
MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma
10.1016/j.jhep.2020.07.039 · doi-reference
MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism
10.1073/pnas.1507228112 · doi-reference
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism
10.1038/nature07823 · doi-reference
